המידע באדיבות מדיקונטקסט
Last Updated: 2001-07-20 15:27:19 EDT (Reuters Health)
WASHINGTON (Reuters Health) – Oridion Systems Ltd. has received clearance from the US Food and Drug Administration to market a noninvasive testing device that detects Helicobacter pylori in a single office visit, the Israeli medical device maker said on Thursday.
Oridion said it received clearance to market its patented BreathID testing device, a unit designed to screen the status of organ specific medical conditions at the point of care.
The company added that it expects a strong response because of the expressed need by doctors for a noninvasive, rapid method to detect peptic ulcers that might lead to gastric cancer.
Oridion said it cannot begin distributing the device until the FDA also clears the urea tablet that is a part of the breath test. The company already has begun to seek the approval of the BreathID testing device in Europe and Japan.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!